Organising pneumonia due to inadequately cleared COVID-19 infection while on rituximab.
Humans
Rituximab
/ therapeutic use
Male
COVID-19
/ complications
SARS-CoV-2
Aged
Immunocompromised Host
Pneumonia, Viral
/ drug therapy
Arthritis, Rheumatoid
/ drug therapy
Coronavirus Infections
/ drug therapy
Cryptogenic Organizing Pneumonia
/ drug therapy
Alanine
/ analogs & derivatives
Pandemics
Antirheumatic Agents
/ therapeutic use
Ritonavir
/ therapeutic use
Betacoronavirus
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antiviral Agents
/ therapeutic use
Organizing Pneumonia
Adenosine Monophosphate
/ analogs & derivatives
COVID-19
Drugs: musculoskeletal and joint diseases
Pneumonia (infectious disease)
Pneumonia (respiratory medicine)
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
A male patient in his 70s with a history of tobacco use, organising pneumonia and rheumatoid arthritis that had been treated for several years with rituximab currently being treated with tocilizumab, presented with progressively worsening shortness of breath, increasing oxygen requirements and weakness. He had a history of COVID-19 infection 6 months prior to presentation. Initial COVID-19 PCR testing at presentation was negative. Bronchoalveolar lavage was positive for COVID-19 but negative for spike antibodies. It was thought that he did not clear his prior COVID-19 infection due to his immunocompromised state while taking rituximab. On recommendation of infectious disease, he was treated with a prolonged course of nirmatrelvir/ritonavir, remdesivir and corticosteroids with significant symptom improvement.
Identifiants
pubmed: 39461843
pii: 17/10/e259153
doi: 10.1136/bcr-2023-259153
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
tocilizumab
I031V2H011
Alanine
OF5P57N2ZX
remdesivir
3QKI37EEHE
Antirheumatic Agents
0
Ritonavir
O3J8G9O825
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Adenosine Monophosphate
415SHH325A
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.